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AT A GLANCE COMMENTARY:
Scientific Knowledge on the Subject:
In the antiretroviral therapy era, community-acquired pneumonia (CAP) remains the 
commonest cause of adult hospitalisation and a major cause of mortality in many sub-
Saharan Africa HIV-affected countries. With the exception of cohorts from South Africa, 
contemporary studies describing CAP aetiology and outcome from the region are either 
small, retrospective or only use limited investigations to define aetiology. Current CAP 
management protocols applied in sub-Saharan Africa are therefore inadequately informed 
by contemporary data. 
What This Study Adds to the Field:
In a large prospective cohort of hospitalised adults in Malawi we show that the major 
burden of hospitalised acute CAP remains in young, HIV-infected patients and that 
Streptococcus pneumoniae, tuberculosis and influenza predominate as the major causes. 
CAP mortality is high compared to populations from well-resourced settings with similar age 
profiles, and is associated with potentially modifiable risk factors including hypoxaemia. 
Death from CAP is poorly predicted by commonly used CAP severity-assessment tools such 
as CURB65.
This article has an online data supplement, which is accessible from this issue's table of 
content online at www.atsjournals.org
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ABSTRACT
Rationale: In the context of rapid antiretroviral therapy (ART) rollout and an increasing 
burden of non-communicable diseases, there are few contemporary data describing the 
aetiology and outcome of community-acquired pneumonia (CAP) in sub-Saharan Africa. 
Objectives: To describe the current aetiology of CAP in Malawi and identify risk factors for 
mortality.
Methods: We conducted a prospective observational study of adults hospitalised with CAP 
to a teaching hospital in Blantyre, Malawi. Aetiology was defined by blood culture, 
Streptococcus pneumoniae urinary antigen detection, sputum mycobacterial culture and 
Xpert MTB/RIF, and nasopharyngeal aspirate multiplex PCR. 
Measurements and Main Results: In 459 patients (285 [62.1%] males; median age 34.7 [IQR: 
29.4-41.9] years), 30-day mortality was 14.6% (64/439) and associated with male sex 
(adjusted odds ratio 2.60 [95% CI: 1.17-5.78]), symptom duration >7 days (2.78 [1.40-5.54]), 
tachycardia (2.99 [1.48-6.06]), hypoxaemia (4.40 [2.03-9.51]) and inability to stand (3.59 
[1.72-7.50]). HIV was common (355/453; 78.4%), frequently newly diagnosed (124/355; 
34.9%), but not associated with mortality. S. pneumoniae (98/458 [21.4%]) and 
Mycobacterium tuberculosis (75/326 [23.0%]) were the most frequently identified 
pathogens. Viral infection occurred in 32.6% (148/454) with influenza (40/454 [8.8%]) most 
common. Bacterial-viral co-infection occurred in 9.1% (28/307). Detection of M. tuberculosis 
was associated with mortality (aOR 2.44 [1.19-5.01]).
Conclusions: In the ART era, CAP in Malawi remains predominantly HIV-associated with a 
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large proportion attributable to potentially vaccine-preventable pathogens. Strategies to 
increase early detection and treatment of tuberculosis and improve supportive care, in 
particular the correction of hypoxaemia, should be evaluated in clinical trials to address CAP-
associated mortality. 
Abstract word count: 250
Keywords: community-acquired pneumonia; HIV; Africa South of the Sahara; Streptococcus 
pneumoniae; pulmonary tuberculosis
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INTRODUCTION
Globally, pneumonia is the commonest infectious cause of death and the second leading 
cause of overall life years lost (1). In sub-Saharan Africa alone, lower respiratory tract 
infections account for 390,000 deaths in older children and adults each year (2). Whilst the 
aetiology and outcome of community-acquired pneumonia (CAP) has been thoroughly 
described in large cohorts of adults in well-resourced settings in Europe and North America 
(3, 4) and more recently in young children (<5 years) from sub-Saharan Africa (5), 
contemporary data on acute CAP in adults from sub-Saharan Africa are limited. With the 
exception of cohorts from South Africa (6, 7), recent studies are either small (8, 9), 
retrospective (10) or only use a restricted panel of investigations to define aetiology (11).
In Malawi – a very low-income country in Southern Africa – pneumonia is the commonest 
cause of adult hospitalisation (12). There is a generalised HIV epidemic (adult prevalence 
10.6% (13)) and high tuberculosis (TB) incidence (159 cases per 100,000 population (14)). 
These factors create a backdrop distinct from most well-resourced settings and common to 
many countries in the region, that is likely to have a substantial bearing on the epidemiology 
and aetiology of CAP; more comprehensive data are therefore crucial to develop appropriate 
context-specific management guidelines (15). Given the continued rollout of antiretroviral 
therapy (ART) (16), recent introduction of infant pneumococcal conjugate vaccination (PCV) 
(17) and the broader context of rapidly increasing life expectancy and emergence of chronic 
non-communicable diseases (18), contemporaneous data are vital. We therefore conducted 
a prospective study of adults hospitalised with CAP to the largest central hospital in Malawi 
to describe aetiology and to identify risk factors for mortality to inform the development of 
local guidelines for antibiotic choice and severity assessment. Some of the results of this 
study have been previously reported in the form of abstracts (19, 20). 
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METHODS
Study setting and design
We conducted a prospective observational study of adults hospitalised with CAP at Queen 
Elizabeth Central Hospital - a 1200 bed teaching hospital that provides free healthcare to the 
1.3 million residents of Blantyre district in Southern Malawi. Ethical approval was provided 
by the Research Ethics Committees of University of Malawi College of Medicine 
(P.11/12/1309) and Liverpool School of Tropical Medicine (13.02). Some patients 
participated in linked case-control studies describing the impact of HIV on influenza severity 
(21) and the association of indoor air pollution exposure with pneumonia (22).
Study procedures
We recruited adults (≥18 years) hospitalised with clinically-diagnosed CAP defined as: 
reported or recorded fever (≥38°C); at least one relevant symptom (cough, chest pain, 
breathlessness, haemoptysis); and at least one focal chest sign (crepitations, pleural rub, 
bronchial breathing, percussive dullness or diminished breath sounds (adapted from (23)). 
Patients with symptoms for more than 14 days, current anti-tuberculous treatment or prior 
admission within the last month were excluded. Further details of the eligibility criteria are 
provided in the online data supplement. Written informed consent was provided by the 
patient, or in the case of incapacity, by their accompanying guardian. 
Patients underwent a standardised clinical assessment on admission, were reviewed daily 
during hospitalisation and then followed at 30-days and 90-days post admission to 
determine vital status. Blood, urine, sputum and nasopharyngeal aspirate (NPA) were 
collected at enrolment. Diagnostic pleural aspiration was performed in patients with 
radiologically confirmed pleural effusion. Clinical care was provided in accordance with local 
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guidelines and directed by the patients’ clinical team.
Radiographic assessment 
Chest radiographs were performed as early as possible after admission and independently 
reported by two radiologists and a study clinician using a standardised form. A consensus 
report of the three assessors was used for analysis. Radiographic pneumonia was defined as 
the presence of consolidation or other parenchymal abnormality (including reticulonodular 
change, cavitation or miliary appearance) or pleural effusion (4). Additional details are 
provided in the online data supplement.
Laboratory testing
Haematological and biochemical analyses were performed by standard methods. HIV status 
was established by sequential rapid tests (Alere Determine™, Japan, and Uni-Gold™, Trinity 
Biotech, Ireland)(24) and CD4 cell count was performed on FACSCount flow cytometer 
(Becton Dickinson, California, USA). Blood cultures were performed using aerobic bottles in 
the BacT/ALERT 3D automated system (bioMérieux, Marcy-L’Etoile, France) and isolates 
identified using standard procedures (25). Urine antigen testing was performed for the 
detection of Streptococcus pneumoniae (BinaxNOW; Alere, Massachusetts, USA) and, in a 
subset of patients, Legionella pneumophila (BinaxNOW; Alere, Massachusetts, USA). A PCR 
assay was performed on NPA specimens for the detection of: adenovirus; bocavirus; 
Chlamydia pneumoniae; coronaviruses 229E, HKU1, OC43 and NL63; enterovirus; human 
metapneumovirus; influenza A and B viruses; Mycoplasma pneumoniae; parainfluenza virus 
types 1 - 4; parechovirus; respiratory syncytial viruses and rhinovirus. Xpert MTB/RIF assay 
(Cepheid; California, USA) and mycobacterial microscopy and culture (BACTEC MGIT 960 
Mycobacterial Detection System; Becton Dickinson, Maryland, USA) were performed on 
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non-induced sputum specimens. When obtained, pleural fluid samples were sent for Gram-
stain, aerobic culture, mycobacterial microscopy and culture, and pneumococcal antigen 
testing. Further details of laboratory methods are provided in the online supplement.
Statistical analysis
Statistical analyses were performed with Stata version 12.1 (StataCorp; Texas, US). We 
tested for differences in continuous variables using Wilcoxon rank-sum test, and categorical 
variables by χ2 test or Fisher’s exact test as appropriate. Differences in microbial aetiology by 
radiographic status controlling for the effect of HIV were examined using the Mantel-
Haenszel method.
Candidate risk factors for 30-day mortality were selected a priori based on literature review 
(26-29). Continuous variables, with the exception of age, were dichotomised at standard cut-
off points (29-32). Univariable analyses were performed using logistic regression to explore 
associations with 30-day mortality. Multivariable models were generated using age, sex, HIV 
status and all variables with a P values <0.2 on univariable analysis, prevalence of at least 5% 
and for which data were available in more than 95% of patients, and then rationalised by 
stepwise backwards elimination with removal of variables with a P value >0.05. The number 
of covariates in the multivariable model were limited to maintain at least 10 events per 
variable (33). Subgroup analyses of HIV-infected patients and those with radiographic 
pneumonia were performed. The association of aetiology with mortality was also assessed 
(see online supplement). All available case information was used in each univariable analysis. 
In multivariable models, we excluded patients with missing data for included variables. 
The prognostic performance of several CAP severity-assessment tools - CURB65 (29), CRB65 
(29), SMRT-CO (simplified version of the SMART-COP tool (34)), modified IDSA/ATS 2007 
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minor criteria (35) and SWAT-Bp (28) - for predicting 30-day mortality was described by 
calculating sensitivity, specificity, positive and negative predictive values, positive and 
negative likelihood ratios and area under the receiver-operating characteristic curve with 
95% confidence intervals (CI). Details of how scores were calculated for each severity-
assessment tool are provided in the online supplement (see Table 4).
RESULTS
Baseline characteristics
Between 15th May 2013 and 31st January 2015 we screened 1711 adult patients, of whom 
489 fulfilled the eligibility criteria, 472 were enrolled and 459 included in the analysis (Figure 
1). The median age was 34.7 years (interquartile range (IQR): 29.4-41.9) and 285 (62.1%) 
were male (Table 1; see Table E1 in the Online Supplement). HIV infection was common 
(355/453; 78.4%; HIV status missing in 6 individuals) and often newly diagnosed (124/355; 
34.9%) whilst other comorbid illnesses were reported infrequently (31/451; 6.9%). 83.3% 
(189/227) of those known to be HIV-infected reported current ART use. Prior pneumonia 
was common (108/457; 23.6%) and associated with HIV (odds ratio (OR) 2.91; 95% CI: 1.46-
6.30). The median length of admission was 7 days (IQR: 4-10). 
Radiographic pneumonia was identified by consensus report in 317 (76.0%) of 417 patients 
with available interpretable chest radiographs with moderate inter-observer agreement 
(Kappa 0.75; 95% CI: 0.69-0.81; Table 1; see Table E2). Pleural effusion was identified in 
118/416 (28.4%), being the sole basis of defining radiographic pneumonia in 38/315 (12.1%). 
The proportion of patients with radiographic pneumonia did not vary with HIV status (HIV-
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infected 247/320 (77.2%) vs. HIV-uninfected 66/91 (72.5%); P=0.36) or with CD4 count (CD4 
<200 cells/mm3 176/222 (79.3%) vs. CD4  200 cells/mm3 49/64 (76.6%), P=0.64; CD4 count 
available in 315/355 (88.7%) HIV-infected patients).
Aetiology
Blood for aerobic culture was obtained from 450 of the 459 (98.0%) of the participants, NPA 
from 455/459 (99.1%) and urine specimen for Streptococcus pneumoniae antigen detection 
from 433/459 (94.3%) with stored specimens available for Legionella antigen testing in 193 
(see Table E5). At least one sputum specimen for a mycobacterial diagnostic test was 
obtained from 322/459 (70.2%) participants: smear microscopy, mycobacterial culture and 
Xpert MTB/RIF assay were completed in 305/459 (66.4%), 273/459 (59.5%) and 308/459 
(67.1%), respectively. A pleural fluid specimen was obtained in 35/459 (7.6%) patients: 
aerobic bacterial culture, Streptococcus pneumoniae antigen detection, mycobacterial smear 
microscopy and culture were completed in 31, 31 and 35 patients respectively. 
Overall at least one potential pathogen was identified in 278/459 (60.6%) patients including 
at least one bacteria in 125/452 (27.7%) and at least one virus in 148/459 (32.6%; Table 2). 
Streptococcus pneumoniae was the most commonly identified organism, present in 98 
(21.4%) of 458 for whom results of blood culture and/or urinary antigen assay were 
available, of whom 92 (93.9%) were identified by detection of urinary antigen alone (see 
Table E5). Pneumococcal aetiology was more common in HIV-uninfected patients (30/97 
(30.9%) vs. 68/355 (19.2%); P=0.01) and those with radiographic pneumonia (83/316 (26.3%) 
vs. 8/100 (8.0%); P<0.001; see Table E6), in particular confluent consolidation (OR 2.51; 95% 
CI: 1.26-4.98; see Table E7). Overall, 26 (5.8%) of 450 patients for whom blood was sent for 
culture were bacteraemic: Salmonella Typhi (n=9), nontyphoidal Salmonella (NTS; n=7) and 
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S. pneumoniae (n=5) were most commonly isolated. S. Typhi was identified more frequently 
in HIV-uninfected patients (5/94 (5%) vs. 3/350 (1%); P=0.02), whilst all cases of NTS 
infection occurred in HIV-infected patients, and both were more common amongst patients 
lacking radiographic pneumonia (see Table E6). Infection with Mycoplasma pneumoniae 
(6/455; 1.3%) and Chlamydia pneumoniae (2/455; 0.4%) were uncommon. None of the 193 
patients tested had a positive Legionella urinary antigen assay result.
Overall, M. tuberculosis was identified in 75 (23.0%) of 326 patients who submitted a 
sputum and/or pleural fluid specimen (Table 2). TB was confirmed by culture in 65/75 
(86.7%) and diagnosed on the basis of Xpert MTB/RIF alone, sputum microscopy alone or 
pleural fluid microscopy alone in 8/75 (10.7%), 1/75 (1.3%) and 1/75 (1.3%) patients, 
respectively (see Table E5). Non-tuberculous mycobacteria were isolated in 8/273 (2.9%) for 
whom sputum for culture was obtained of whom 1 was smear positive. The frequency of TB 
did not differ significantly between the groups with and without radiographic pneumonia 
(58/232 (25%) vs. 13/68 (19.1%); see Table E6), although in the latter, TB displaced S. 
pneumoniae as the most commonly identified pathogen, with all cases occurring in HIV-
infected patients. 
Influenza (40/454; 8.8%), adenovirus (35/455; 7.7%) and coronavirus (31/455; 6.8%) were 
the most commonly detected viruses. Detection of these respiratory viruses was not 
associated with HIV status or the presence of radiographic pneumonia (see Tables 2 and E6).
Co-infection relationships were investigated in 307 patients (66.9% of cohort) for whom 
results for blood culture, pneumococcal urine antigen, sputum mycobacterial culture and/or 
Xpert MTB/RIF, NPA PCR were available. At least one organism was detected in 206/307 
(67.1%) and co-infection with 2 or more organisms was present in 67/307 (21.8%; Figure 2); 
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the combination of bacterial-viral co-infection was most frequent (28/307; 9.1%). S. 
pneumoniae was co-detected in one-fifth of patients with influenza (6/31; 19.4%). M. 
tuberculosis was isolated in 9.6% (7/73) of those with S. pneumoniae (see Table E8). 
Detection of multiple organisms did not vary with HIV status (54/243 (22.2%) vs. 12/62 
(19.4%)).
Mortality
439 of 459 (95.6%) patients were successfully followed to 30 days of whom 64 (14.6%) had 
died, including 15 and 31 within the first 3 and 7 days following admission, respectively 
(Table 1). 418 were followed to 90 days of whom an additional 23 had died. Male sex (aOR 
2.60; 95% CI: 1.17-5.78), pre-presentation symptom duration >7 days (aOR 2.78; 95% CI: 
1.40-5.54), heart rate ≥125 per minute (aOR 2.99; 95% CI: 1.48-6.06), oxygen saturations 
<90% (aOR 4.40; 95% CI: 2.03-9.51) and inability to stand (aOR 3.59; 95% CI: 1.72-7.50) were 
independently associated with 30-day mortality (Table 3). Neither age nor any underlying 
comorbid illness, including HIV, or initial antimicrobial treatment was found to be 
significantly associated with 30-day mortality. Detection of S. pneumoniae was associated 
with reduced mortality (aOR 0.40; 95% CI: 0.17-0.91; see Table E9), whilst TB was associated 
with increased mortality (aOR 2.44; 95% CI: 1.19-5.01). Mortality did not vary with detection 
of multiple organisms compared to a single organism (5/65 (7.7%) vs. 13/135 (9.6%); 
P=0.80). 
In a subgroup analysis of the 342 HIV-infected patients followed to day 30, symptom 
duration >7 days (aOR 3.56; 95% CI: 1.60-7.93), heart rate ≥125 per minute (aOR 3.06; 95% 
CI: 1.40-6.71), oxygen saturations <90% (aOR 2.97; 95% CI: 1.28-6.88), inability to stand (aOR 
4.25; 95% CI: 1.84-9.79) and CD4 count <50 cells/mm3 (aOR 2.30; 95% CI: 1.07-4.92) were 
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associated with mortality in multivariable analysis (see Table E10). CD4 count <200 
cells/mm3 was not associated with mortality (OR 1.63; 95% CI: 0.69-3.83). In the subgroup of 
305 patients with radiographic pneumonia followed to day 30, symptom duration >7 days 
(aOR 3.30; 95% CI: 1.37-7.96), heart rate ≥125 per minute (aOR 2.66; 95% CI: 1.08-6.57) and 
multilobar consolidation (aOR 2.75; 95% CI: 1.17-6.47) were significantly associated with 
mortality, with a trend towards an association for inability to stand (aOR 2.63; 95% CI: 1.00-
6.89; see Table E11). 30-day mortality was however significantly higher in the small group of 
patients for whom a chest radiograph was unavailable (17/36 (47.2%) vs. 47/403 (11.7%); 
P<0.0001; see Table E3). 
Prognostic performance of severity-assessment tools
Of the CAP severity-assessment tools examined, SMRT-CO had the highest sensitivity (89.7%; 
95% CI: 72.6-97.8), negative predictive value (96.8%; CI: 91.0-99.3%) and overall 
discriminatory capability (AUROC 0.66; 95% CI: 0.57-0.75) for 30-day mortality (Table 4). 
CURB65 had poor sensitivity and discriminatory capability. Only 38 (8.8%) patients had 
‘severe CAP’ by CURB65 (i.e. score ≥3) and mortality amongst those with ‘mild CAP’ (i.e. 
CURB65 ≤1) was 10.8% (29/268). The prognostic performance of each tool was similarly poor 
in the subgroup with radiographic pneumonia (see Table E12).
DISCUSSION 
In this prospective study of acute CAP in adults that is amongst the largest conducted in sub-
Saharan Africa, we have shown that: the burden of hospitalised pneumonia in adults 
predominantly remains in young, HIV-infected patients; tuberculosis and vaccine-
preventable pathogens such as S. pneumoniae and influenza are common; mortality is 
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substantial and associated with potentially modifiable risk factors but poorly predicted by 
widely-used CAP severity-assessment tools. 
Although completed within the era of ART scale-up, 35% of HIV-infected patients were 
newly diagnosed, 17% of those with known HIV were not receiving ART and more than 
three-quarters had advanced immunosuppression (i.e. CD4 <200 cells/mm3). Further 
substantial reductions in CAP incidence may therefore be achieved by improved HIV testing 
and linkage to early initiation of ART (36). 
At first glance, the overall crude mortality rate of 14.6% is comparable to that seen in well-
resourced settings (26, 29, 37). However, a recent UK cohort reported 30-day mortality of 
1.5% in patients under 50 (38), suggesting a substantially higher age-adjusted mortality rate 
in our cohort. The identified associations of TB and uncorrected hypoxaemia with death, 
may explain some of this apparent large discrepancy in mortality rate. In keeping with other 
studies of acute CAP (7, 27, 28), we did not find evidence that HIV overall influenced 
outcome; increased mortality was evident in only the most profoundly 
immunocompromised with CD4 cell count <50 cells/mL. 
Given the observed strong association of hypoxaemia with mortality, expansion of 
supplemental oxygen provision, which across much of sub-Saharan Africa is currently 
severely limited (39), represents an obvious strategy to be evaluated in an effort to improve 
CAP outcomes. Programmatic interventions in children in low-resource settings based on 
improved oxygen supply using oxygen concentrators have been associated with a 35% 
reduction in mortality (40). The lack of association between respiratory rate and mortality 
underlines the importance of expanding the availability of pulse oximetry in tandem. 
Similarly, the association of pre-presentation symptom duration with mortality suggests that 
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interventions to improve patient education to alter healthcare-seeking behaviour or referral 
mechanisms within community healthcare centres should be considered. The continued 
substantial mortality rate beyond day 30 also warrants further study to devise targeted 
interventions to enhance care following discharge from hospital. 
The use of objective CAP severity assessment tools has been shown to improve both the 
recognition of patients with severe CAP likely to require intensive care support (41) and 
those with mild disease who can be safely managed as outpatients (42). Current South 
African CAP guidelines recommend that CURB65 is used to inform site of care and initial 
antimicrobial treatment (43). However, we found that CURB65 showed poor prognostic 
performance in predicting 30-day mortality in this cohort compared to its performance in 
CAP cohorts from well-resourced settings (44). This variation likely reflects differences in 
microbial aetiology, demographics and comorbidity profiles between this cohort and the 
patient populations in which CURB65 was derived (29, 37), and underlines the importance of 
prospective validation of prognostic tools in relevant settings (29, 44). The similarly poor 
performance of the SWAT-Bp score that was derived in a LRTI cohort from Malawi (28), 
however, highlights the challenges of developing a simple and accurate locally-adapted tool. 
Rather than attempting to derive a single tool capable of accurately predicting mortality 
across the whole spectrum of disease severity, a tool with high negative predictive 
performance aimed at identifying those patients with a low risk of adverse outcome suitable 
for outpatient management may be more feasible and equally useful. In this respect, the 
SMRT-CO tool performed well with a negative predictive value of 96.8%, but the inclusion of 
a radiographic parameter (i.e. multilobar involvement (34)) limits its use as a triage tool in 
settings where chest radiography might not be readily available.
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Recent CAP studies corroborate our observation that S. pneumoniae remains the 
commonest identified cause of adult CAP in sub-Saharan Africa (6, 10, 27). Universal infant 
vaccination with PCV was introduced in Malawi in 2011, approximately 2.5 years before the 
start of recruitment. Following the introduction of PCV in the US and South Africa, rates of 
adult pneumococcal disease – including pneumonia hospitalisations – fell rapidly as a result 
of indirect protection due to reduced pneumococcal transmission from vaccine recipients 
(45, 46). Further studies are needed to describe the serotype distribution of pneumococcal 
pneumonia in Malawi, to determine whether targeted vaccination programmes of at risk 
groups may be beneficial to tackle the persistent burden of adult disease. Recently 
developed urinary assays that can detect serotype-specific antigens in non-invasive 
pneumococcal pneumonia may provide a more comprehensive description (47). 
When adequate diagnostic tests are performed, TB is identified in a substantial proportion of 
patients presenting with acute CAP in sub-Saharan Africa with the major burden of disease 
and associated mortality occurring in HIV-infected individuals (7-9, 27). At 23% of those 
tested and 16% of the overall cohort, the frequency of TB is similar to that previously 
reported (7-9, 27), but probably underestimates the true burden given the reliance on 
spontaneously expectorated sputum specimens and a single specimen submitted for culture. 
In most sub-Saharan African settings, laboratory diagnosis of TB has until recently relied on 
sputum smear microscopy that has poor sensitivity, particularly for HIV-associated TB. The 
WHO has advocated an empirical “step-up” approach, whereby anti-tuberculous treatment 
is initiated for HIV-infected adults with features of severe respiratory infection and negative 
sputum smears who fail to improve after 3-5 days of antibacterial treatment (48). Whilst this 
approach may limit inappropriate anti-tuberculous treatment, it may miss up to 20% of 
patients with culture positive TB and risks delaying treatment in a group of patients with a 
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very high risk of early death (49). The increasingly available Xpert MTB/RIF assay used in this 
study offers much improved sensitivity and is now recommended as the first-line diagnostic 
for HIV-associated TB (50). Rapid urine-based diagnostics (e.g. urine Xpert MTB/RIF, 
mycobacterial glycopeptide lipoarabinomannan assay) may have a complementary role to 
guide initiation of anti-tuberculous treatment, particularly for acutely ill patients from whom 
sputum is frequently unobtainable (51, 52).
In keeping with recent CAP studies from well-resourced settings that have utilised molecular 
diagnostics (4, 53), we identified high rates of co-infection with multiple organisms, most 
commonly bacterial-viral co-isolation. Defining the clinical significance of each organism 
detected is challenging, particularly amongst immunocompromised individuals. Whilst co-
isolation may reflect genuine co-pathogenicity or simply detection of bystander colonising 
organisms, more complex relationships in which one organism facilitates the acquisition or 
pathogenesis of another (e.g. influenza and S. pneumoniae (54)) are possible. Bacterial-viral 
coinfection has been associated with altered levels of innate immune factors (e.g. CRP, IP10 
(55)) and more severe clinical course (56). Further work is needed to define the implications 
for CAP therapy and prevention. 
Radiographic facilities are limited in most healthcare facilities in sub-Saharan Africa where 
the majority of CAP patients are initially managed. Whilst the clinical case definition used in 
this study may have missed some patients with radiographic pneumonia who lacked focal 
signs at the time of recruitment it nonetheless reflects routine clinical practice and usefully 
provides data to show how the aetiological spectrum of disease varies with chest radiograph 
findings (57). The association of radiographic changes compatible with infection with S. 
pneumoniae is unsurprising. Although still relatively uncommon, the greater prevalence of 
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invasive Salmonella infection amongst those lacking radiographic pneumonia has important 
implications for antimicrobial management. Whilst specific radiological features were 
statistically associated with certain pathogens, the marked inter-observer variability in 
interpretation of these features suggests that the clinical utility of this approach is limited. 
In recruiting patients exclusively from a single referral hospital, this study shares the 
limitations common to many CAP observational cohorts. Most patients were seen at another 
facility prior to attendance; how they were selected for referral and correspondingly, the 
characteristics and outcome of those treated at home is unknown. Hence, the applicability 
of the findings to community level settings is potentially limited. Extrapolation of these 
findings to other countries in sub-Saharan Africa must also be done cautiously because of 
the potential impact that variations in factors such as TB incidence, HIV-prevalence and 
climate may have on CAP epidemiology and aetiology. Given limitations of the healthcare 
infrastructure in Malawi, chronic comorbid illnesses may be underdiagnosed. Inconsistencies 
in drug supply, equipment provision and staff experience may result in variations in CAP 
treatment that may impact patient outcome but are not fully accounted for in analyses. The 
description of CAP aetiology was limited by the lack of sputum microscopy and culture which 
may have increased the detection of bacterial pathogens such as Haemophilus influenzae as 
has been described in previous studies from the region (27, 58). Similarly, we were unable to 
support invasive respiratory sampling for diagnostic testing for Pneumocystis jirovecii (PCP) 
and other HIV-associated opportunistic pathogens. The low rate of bacteraemia observed 
may relate to both pre-hospital antibiotic use and antibiotic initiation prior to blood couture 
collection in hospital which occurred in up to one-third of patients. Interpretation of the 
significance of respiratory pathogen multiplex PCR results, particularly for respiratory 
viruses, is hampered by the lack of data from an appropriate control population. The relative 
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contribution of pathogens with seasonal transmission patterns (e.g. influenza) may also have 
been skewed by a recruitment period that spanned two incomplete years.
In conclusion, more than a decade after the introduction of ART, the major burden of CAP in 
Malawi remains in young, HIV patients rather than the elderly patients with chronic non-
communicable comorbidities that predominate in well-resourced settings. Accordingly, 
context-specific approaches to severity assessment and defining empirical antimicrobial 
treatment are needed. The predominance of S. pneumoniae and influenza suggest significant 
opportunities for CAP prevention through targeted vaccination programmes. Strategies to 
encourage prompt patient presentation, to increase early detection and treatment of TB and 
to improve supportive care, in particular the correction of hypoxaemia, should be evaluated 
in clinical trials to address the high burden of CAP-related mortality. 
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Figure 1. Recruitment and follow-up of a cohort of Malawian adults hospitalised 
community-acquired pneumonia. *Some patients excluded for multiple reasons hence totals 
exceed total number excluded. 
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Figure 2. Bacterial, viral and mycobacterial infection in isolation and combination in 
Malawian adults hospitalised with community-acquired pneumonia. Aetiology defined by 
blood culture, Streptococcus pneumoniae urinary antigen detection, sputum mycobacterial 
culture and Xpert MTB/RIF, and nasopharyngeal aspirate respiratory pathogen multiplex 
PCR. Analysis restricted to 307 patients with results available for all tests.
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Table 1. Demographic, clinical and radiographic characteristics of 459 Malawian adults 
hospitalised with community-acquired pneumonia.
Characteristic No. (%) of episodes
Demographics
Male sex 285/459 (62.1)
Age* 34.7 (29.4-41.9)
HIV status
HIV positive†
Newly diagnosed
355/453
124/355
(78.4)
(34.9)
CD4 cell count (cells/mm3)†
All HIV-positive
Newly diagnosed HIV-positive
99
93
(44-193)
(43-179)
ART use in known HIV-positive† 189/227 (83.3)
Medical history
Any other comorbid condition 31/451 (6.9)
Chronic lung disease‡ 15/452 (3.3)
Chronic heart disease§ 3/452 (0.7)
Hypertension 8/452 (1.8)
Previous tuberculosisll 84/458 (18.3)
Previous pneumonia in last 5 years** 108/457 (23.6)
Pregnancy 2/174 (1.2)
Current smoker 50/457 (10.9)
Pre-hospital/clinic attendance & treatment
Attended another health facility†† 283/458 (61.8)
Antibiotics within 2 weeks‡‡ 280/455 (61.5)
Antimalarials within 2 weeks 79/457 (17.3)
Traditional remedies within 2 weeks 40/456 (8.8)
Baseline observations
Temperature (°C)*
<35 or ≥40
37.9
14/459
(37.1-38.9)
(3.1)
Systolic BP (mmHg)*
<90
106
86/454
(93-121)
(18.9)
Diastolic BP (mmHg)*
≤60
68
143/454
(59-78)
(31.5)
Heart rate (beats/min)*
≥125
118
176/458
(102-132)
(38.4)
Respiratory rate (breaths/min)*
≥30 
29
213/446
(26-34)
(47.8)
Oxygen saturations (%)*
<90
95
73/450
(91-98)
 (16.2)
Body mass index (kg/m2)*
<18.5
19.9
132/444
(18.2-21.8)
(29.7)
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Characteristic No. (%) of episodes
Baseline laboratory results
Haemoglobin (g/dL)*
<8
11
74/449
(9.0-12.8)
(16.5)
White blood cells (x 109 cells/L)*
<4
≥15
7.7
67/448
x63/448
(5.0-11.4)
(15.0)
(14.1)
Urea (mmol/L)*
>7
4.8
137/450
(3.3-8.0)
(30.4)
Creatinine (μmol/L)*
>120
76
76/448
(59-100)
(17.0)
Radiological features§§
Radiographic pneumonia 317/417 (76.0)
Consolidation 251/313 (80.2)
Multilobar involvement 73/247 (29.6)
Cavitation 20/317 (6.3)
Pleural effusion 118/315 (37.5)
Outcomellll
Inpatient mortality 51/457 (11.2)
Day 30 mortality 64/439 (14.6)
Day 90 mortality 87/418 (20.8)
Definition of abbreviations: ART = antiretroviral therapy; BP = blood pressure; IQR = 
interquartile range
Data are n/N (%)unless indicated by * where median and interquartile range are 
shown. Variation in denominator reflecting missing data unless further specified.
†HIV status missing in 6 patients; CD4 count missing in 40 of all with HIV; ART usage 
missing in 4 with known HIV.
‡Chronic lung disease includes asthma, COPD and bronchiectasis. 
§Chronic heart disease includes congestive cardiac failure, cor pulmonale and dilated 
cardiomyopathy. 
llAny previous episode of treated tuberculosis regardless of site and confirmation. 
**Any prior episode within the last 5 years of a syndrome compatible with lower 
respiratory tract infection reviewed in a healthcare facility and treated with 
antibiotics. 
††Included attendance to other hospital, health centre, private clinic, traditional 
healer or pharmacy. 
‡‡Excluded co-trimoxazole prophylaxis in HIV-infected individuals.
§§Chest radiographs available in 421 patients; reports based on consensus grading of 
assessors and denominator may vary when consensus not obtained.  
llllStatus at hospital discharge, day 30 and day 90 missing in 2, 20 and 41, respectively.
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Table 2. Aetiology of community-acquired pneumonia in Malawian adults stratified by HIV status.
Organism
All*
(n=459)
      HIV-positive
        (n=355)
HIV-negative
(n=98)
P for difference†
Streptococcus pneumoniae 98/458 (21.4) 68/355 (19.2) 30/97 (30.9) 0.01
Salmonella Typhi 10/450 (2.2) 4/350 (1.1) 5/94 (5.3) 0.02‡
Nontyphoidal Salmonella§ 7/450 (1.6) 7/350 (2) 0/94 (0) 0.35‡
Other GNEBll 3/450 (0.7) 3/350 (0.9) 0/94 (0) 1.00‡
Staphylococcus aureus 2/450 (0.4) 1/350 (0.3) 1/94 (1.1) 0.38‡
Mycoplasma pneumoniae 6/455 (1.3) 6/355 (1.7) 0/98 (0) 0.35‡
Chlamydia pneumoniae 2/455 (0.4) 0/355 (0) 2/98 (2.0) 0.05‡
Legionella pneumophila 0/193 (0) 0/154 (0) 0/38 (0) -
Mycobacterium tuberculosis 75/326 (23.0) 64/257 (24.9) 10/64 (15.6) 0.12
Nontuberculous mycobacteria 8/273 (2.9) 5/217 (2.3) 3/52 (5.8) 0.19‡
Influenza viruses 40/454 (8.8) 30/354 (8.5) 9/98 (9.2) 0.83
Adenovirus 35/455 (7.7) 30/355 (8.5) 5/98 (5.1) 0.39‡
Coronaviruses 31/455 (6.8) 28/355 (7.9) 3/98 (3.1) 0.11‡
Parainfluenza viruses 17/455 (3.7) 15/355 (4.2) 1/98 (1) 0.21‡
Rhinovirus 17/455 (3.7) 15/355 (4.2) 2/98 (2) 0.55‡
Bocavirus 13/455 (2.9) 13/355 (3.6) 0/98 (0) 0.08‡
Metapneumovirus 9/455 (2.0) 8/355 (2.3) 1/98 (1) 0.69‡
RSV 8/455 (1.8) 4/355 (1.1) 3/98 (3.1) 0.18‡
Enterovirus 5/455 (1.1) 5/355 (1.4) 0/98 (0) 0.59‡
Parechovirus 5/455 (1.1) 5/355 (1.4) 0/98 (0) 0.59‡
No pathogen detected 181/459 (39.4) 137/355 (38.6) 42/98 (42.9) 0.44
Definition of abbreviations: GNEB = Gram-negative enteric bacilli; OR = odds ratio; RSV = respiratory syncytial virus.
Data are n/N (%). Denominators indicate number of patients with at least one relevant test available. S. pneumoniae 
diagnosis based on combination of blood and pleural fluid culture and antigen assay of urine and pleural fluid. M. 
tuberculosis based on combination of sputum microscopy, culture and Xpert MTB/RIF and pleural fluid culture. Other 
organisms based on single test. Column totals exceed number of patients since multiple organisms detected in some.
*Includes 6 patients with missing HIV status in whom the following organisms were identified: Salmonella Typhi, 1; 
Mycobacterium tuberculosis, 1; Influenza, 1; Parainfluenza, 1; RSV, 1; No pathogen detected, 2.
†χ2 test unless otherwise stated. 
‡Fisher’s exact test. 
§S. Enteritidis and S. Typhimurium combined.
llEscherichia coli and Enterobacter cloacae combined.
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Table 3. Association of candidate clinical and laboratory risk factors with 30-day mortality 
in Malawian adults hospitalised with community-acquired pneumonia.
Univariable analysis Multivariable analysis
Characteristic
Day 30 survivors
(n=375)
Day 30 
mortality
(n=64) OR (95% CI) P aOR (95% CI) P
Male sex 224/375 (59.7) 52/64 (81.3) 2.92 (1.51-5.66) 0.001 2.60 (1.17-5.78) 0.02
Age (yrs) 34 (29-42) 36 (32-42) 1.00 (0.98-1.03) 0.73 1.00 (0.97-1.03) 0.93
Current smoker 41/373 (11.0) 7/64 (10.9) 0.99 (0.43-2.33) 0.99 - -
Regular alcohol use 92/373 (24.7) 23/63 (36.5) 1.76 (1.00-3.09) 0.05 - -
Unemployed 109/357 (30.5) 13/61 (21.3) 0.62 (0.32-1.18) 0.15 - -
HIV-positive 288/370 (77.8) 54/64 (84.4) 1.53 (0.75-3.15) 0.24 1.26 (0.49-3.21) 0.63
Chronic lung disease 11/371 (3.0) 3/61 (4.9) 1.69 (0.46-6.23) 0.43 -* -
Chronic heart disease 2/370 (0.5) 1/61 (1.6) 3.07 (0.27-34.35) 0.36 -* -
Renal disease 0/371 (0) 1/61 (1.6) - - -* -
Pre-presentation 
symptoms >7 days
138/374 (36.9) 36/63 (57.1) 2.28 (1.33-3.92) 0.003 2.78 (1.40-5.54) 0.004
Travel time ≥1 hour 278/373 (74.5) 51/62 (82.3) 1.58 (0.79-3.16) 0.19 - -
Previous review 231/375 (61.6) 42/63 (66.7) 1.25 (0.71-2.19) 0.44 - -
Temperature <35 or ≥40 °C 13/375 (3.5) 1/64 (1.6) 0.44 (0.06-3.44) 0.44 -* -
Systolic BP <90 mmHg 66/371 (17.8) 17/63 (27.0) 1.71 (0.92-3.16) 0.09 - -
Diastolic BP ≤60 mmHg 112/371 (30.2) 28/63 (44.4) 1.85 (1.07-3.19) 0.03 -‡ -
Mean arterial BP <65 
mmHg
46/371 (12.4) 15/63 (23.8) 2.21 (1.14-4.26) 0.02 -‡ -
Heart rate ≥125 /min 135/374 (36.1) 37/64 (57.8) 2.43 (1.42-4.16) 0.001 2.99 (1.48-6.06) 0.002
Resp. rate≥30 /min) 172/364 (47.3) 33/62 (53.2) 1.27 (0.74-2.18) 0.39 - -
Oxygen satn <90 % 45/368 (12.2) 27/63 (42.9) 5.38 (2.99-9.70) <0.0001 4.40 (2.03-9.51) <0.001
BMI <18.5 kg/m2 108/366 (29.5) 20/61 (32.8) 1.17 (0.65-2.08) 0.61 -§ -
MUAC <230 mm 103/371 (27.8) 14/63 (22.2) 0.74 (0.39-1.40) 0.36 - -
Confusion 2/374 (0.5) 3/64 (4.7) 9.15 (1.50-55.87) 0.02 -* -
Inability to stand 57/375 (15.2) 30/64 (46.9) 4.92 (2.79-8.67) <0.0001 3.59 (1.72-7.50) 0.001
Haemoglobin <8 g/dL 55/368 (15.0) 18/61 (29.5) 2.38 (1.28-4.43) 0.006 - -
White cell count <4 x 109/L 50/367 (13.6) 15/61 (24.6) 2.07 (1.07-3.98) 0.03 - -
Platelets <100 x 109/L 58/368 (15.8) 14/61 (23.0) 1.59 (0.82-3.08) 0.17 - -
Urea >7 mmol/L 107/370 (28.9) 27/60 (45.0) 2.01 (1.15-3.51) 0.01 - -
Creatinine >120 μmol/L 56/369 (15.2) 15/59 (25.4) 1.91 (0.99-3.65) 0.05 - ll -
Glucose ≥14 mmol/L 0/330 (0) 0/53 (0) - - -† -
Definition of abbreviations: BP = blood pressure; BMI = body mass index; CI = confidence interval; MUAC = mid-upper arm 
circumference; OR = odds ratio; Resp. = respiratory
For age (in italics) data shown as median and interquartile range. Otherwise data shown as n/N (%) with variation in 
denominator compared to column header reflecting missing data. Univariable and multivariable analyses by logistic 
regression. For age, odds ratio indicates change in risk of mortality with each year increase. 20 patients of overall study 
cohort of 459 excluded due to unknown 30-day outcome. Final multivariable analysis based on 380 patients with complete 
results for all included parameters.  
*Excluded from multivariable analysis because of prevalence ≤5%. 
†Excluded from multivariable analysis because data were missing for >5% of patients.
‡Excluded a priori from multivariable analysis because of assumed collinearity with systolic blood pressure. 
§Excluded a priori because of assumed collinearity with MUAC. 
llExcluded a priori because of assumed collinearity with urea. 
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Table 4. Accuracy of pneumonia severity-assessment tools for predicting 30-day mortality in a cohort of Malawian adults hospitalised with 
community-acquired pneumonia cohort.
Score group n*
Sensitivity % 
(95% CI)
Specificity %
(95% CI)
PPV %
(95% CI)
NPV %
(95% CI)
Positive LR
(95% CI)
Negative LR
(95% CI)
AUROC
(95% CI)
CURB65 ≥3 412 14.0 (6.3-25.8) 91.5 (88.2-94.2) 21.1 (9.6-37.3) 86.9 (83.1-90.1) 1.66 (0.80-3.44) 0.94 (0.84-1.05 0.60 (0.52-0.67)
CRB65 ≥2 421 27.9 (17.1-40.8) 81.9 (77.6-85.8) 20.7 (12.6-31.1) 87.0 (83.0-90.4) 1.54 (0.97-2.44) 0.88 (0.75-1.04) 0.57 (0.50-0.65)
SMRT-CO ≥2 280 89.7 (72.6-97.8) 36.7 (30.7-42.9) 14.1 (9.4-19.9) 96.8 (91.0-99.3) 1.42 (1.21-1.65) 0.28 (0.10-0.83) 0.66 (0.57-0.75)
Modified IDSA/ATS 
minor criteria ≥3
272 48.3 (29.4-67.5) 72.0 (65.9-77.6) 17.1 (9.7-27.0) 92.1 (87.3-95.5) 1.73 (1.13-2.64) 0.72 (0.50-1.03) 0.66 (0.56-0.75)
SWAT-Bp ≥3 427 54.1 (40.8-66.9) 68.3 (63.3-73.0) 22.1 (15.8-29.7) 89.9 (85.8-93.2) 1.71 (1.30-2.25) 0.67 (0.51-0.89) 0.65 (0.57-0.72)
Definition of abbreviations: AUROC = area under receiver-operating characteristic curve; CI = confidence interval; CURB65 = tool based on presence of confusion, urea >7mmol/L, respiratory rate 
≥30/min, systolic blood pressure <90mmHg and/or diastolic blood pressure ≤60mmHg, age ≥65 (29); CRB65 = as per CURB65 with exclusion of urea (29); IDSA/ATS = modified version of 
Infectious Disease Society of America/American Thoracic Society criteria based on presence of respiratory rate 30/min, oxygen saturations 90% (used as a surrogate for arterial oxygen 
pressure/fraction of inspired oxygen (PaO2/FiO2) ratio 250 criterion included in the published tool), multilobar infiltrates, confusion/disorientation, urea 7.1 mmol/L, white blood cell count <4 
x109 cells/L, platelets <100 x109 cells/L, temperature <36C, systolic blood pressure < 90 mmHg (used as a surrogate for hypotension requiring aggressive fluid resuscitation; (35); LR = likelihood 
ratio; NPV = negative predictive value; PPV = positive predictive value; SMRT-CO = tool based on presence of systolic blood pressure < 90 mmHg, multilobar consolidation, respiratory rate 
25/min if 50 years or 30/min if >50 years, heart rate 125/min, confusion and oxygen saturations 93% if 50 yrs or 90% if >50 yrs (34); SWAT-Bp = tool based on male sex, wasting, non-
ambulatory status, temperature <35C or >38C and systolic blood pressure <100 mmHg or diastolic blood pressure <60 mmHg (28). For each tool, the performance characteristics displayed are 
those using the scoring threshold for “severe CAP” as suggested by the authors. *Score calculated in varying number of patients depending on availability of results for component parameters; 
SMRT-CO & modified IDSA/ATS minor criteria include radiological parameter hence only calculated in those with radiographic pneumonia.
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Online Data Supplement
SUPPLEMENTARY METHODS
Study design and conduct
We conducted a prospective observational study of adults hospitalised with CAP at 
Queen Elizabeth Central Hospital (QECH) - a 1200 bed teaching hospital that provides free 
healthcare to the 1.3 million residents of Blantyre district in Southern Malawi. 
Recruitment commenced on 15th May 2013 and continued until 31st January 2015. 
Participant follow-up was completed by 28th May 2015. 
Detailed inclusion and exclusion criteria
Clinical aspects of the study were completed by a dedicated team of research nurses and 
clinical officers who had received extensive training prior to study initiation. Study 
investigators (SA, AH, HJ, JH and TM) accompanied the clinical study team on their daily 
rounds at least weekly to evaluate data quality and consistency of data collection. 
Patients with features of respiratory illness or infection were screened on arrival in the 
hospital emergency department or on the medical wards within 24 hours of admission. 
Consenting adults with clinically diagnosed community-acquired pneumonia (CAP) as 
defined by the eligibility criteria below (summarised in the Methods section) were 
recruited.
Inclusion criteria
We recruited adults (≥18 years) hospitalised with clinically-diagnosed CAP defined as: 
reported or recorded fever (≥38°C); at least one relevant symptom (cough, chest pain, 
breathlessness, haemoptysis); and at least one focal chest sign (crepitations, pleural rub, 
bronchial breathing, percussive dullness or diminished breath sounds) (E1).
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Exclusion criteria
Patients with any of the following were excluded from participation: symptoms for 
greater than 14 days; suspected co-existent meningitis; pre-admission diagnosis of 
terminal illness (e.g. metastatic malignancy, terminal AIDS); current anti-tuberculous 
treatment; admission to hospital more than 24 hours previously; prior hospitalisation 
within preceding 4 weeks; or prior participation in the study.
Clinical assessment and follow-up
For each participant, the study team completed a standardised clinical assessment 
consisting of a comprehensive medical history, physical examination and measurement of 
physiological observations. Information was obtained via direct questioning of the study 
participant (or accompanying guardian) and by reference to medical notes and health 
passport. Physiological observations were measured by the study team on admission or 
abstracted from the medical notes for patients recruited from the medical wards. In lieu 
of a validated cognitive assessment tool that is not available in Malawi, the presence of 
confusion was determined using three standardised questions assessing orientation in 
time, place and person. 
Study participants were reviewed on a daily basis each morning until discharge or 14 days 
post-admission. At the point of hospital discharge or inpatient death, the study team 
reviewed the clinical notes and recorded details of treatment administered. Patients 
surviving to discharge were contacted at 30-days and 90-days post admission to 
determine vital status and hospital readmission. Two attempts were made to obtain this 
information by phone call to the patient or their guardian; if unsuccessful field workers 
visited the patient’s home.
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Patients with influenza formed the case population of a linked case-control study 
describing the impact of HIV on influenza severity (E2). Some patients with radiographic 
pneumonia who survived to discharge also participated in a further case-control study of 
the association of exposure to indoor air pollution with the occurrence of pneumonia 
(E3).
Radiographic assessment
During the period of the study, there was no functional portable radiograph machine 
available at QECH; consequently, radiographs were not performed in clinically unstable 
patients that could not be safely transferred to the radiology department. Plain chest 
radiograph films were photographed on a light-box using a standard light-reflex digital 
camera mounted on a tripod in a darkened room. All study radiograph reports were 
generated by review of the set of digital images. 
Chest radiographs were reported independently by two study radiologists (EJ and SG) and 
the study Principal Investigator (SA, an Infectious Diseases Resident Physician). All 
reporters were blinded to demographic and clinical data at the time of reporting. 
Radiographs were reported using a standardised form, that was piloted prior to use for 
study reporting to ensure consistent application. Definitions of radiological features were 
based on the Fleischner Society: Glossary of terms for thoracic imaging (E4). 
Parenchymal abnormalities were categorised as consolidation, reticulonodular change, 
miliary appearance and cavitation. Consolidation was further characterised in terms of its 
quality (confluent or patchy), extent (segmental, lobar or multifocal) and distribution 
(lower, mid- and/or upper zone, or diffuse). Radiographic pneumonia was defined as the 
presence of consolidation or other parenchymal abnormality (including reticulonodular 
change, cavitation or miliary appearance) or pleural effusion (E5). Multilobar 
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consolidation was not specifically reported on the form; consolidation was considered to 
be multilobar if characterised as diffuse, present in two or more non-contiguous lung 
zones regardless of extent or present in two or more contiguous lung zones and 
characterised as multifocal. Multifocal consolidation within a single lung zone was not 
classified as multilobar. Study analyses were based on a consensus report for each 
specific feature. If there was disagreement between the reporters, the majority opinion 
was used. Variability of interpretation was assessed by calculating average agreement 
and kappa coefficient.
Specimen collection, processing and testing
Haematology and biochemistry
Full blood count was performed on whole blood specimens using a Beckman Coulter HmX 
Haematology Analyser (Beckman Coulter, California, USA). Whole blood specimens for 
biochemical assays were centrifuged within 24 hours of collection. Urea and creatinine 
concentrations were measured in serum specimens using a Beckman Coulter AU480 
Chemistry Analyser (Beckman Coulter, California, USA). CD4 cell counts were measured 
using a Becton Dickinson FACSCount (Becton Dickinson, California, USA) or a Partec 
CyFlow CD4 Analyser (Sysmex Partec, Görlitz, Germany).
Bacteriology
Blood cultures were performed using standard aerobic bottles in the BacT/ALERT 3D 
automated system (bioMérieux, Marcy-L’Etoile, France) as previously described (E6). All 
isolates were identified using standard diagnostic procedures (E7). Coagulase-negative 
Staphylococci, Bacillus spp., Micrococcus spp. and diphtheroids were considered as 
contaminants. 
Urine was collected in standard containers and refrigerated. The BinaxNOW® urine 
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antigen test for Streptococcus pneumoniae (Alere, Massachusetts, USA) was performed in 
accordance with the manufacturer’s instructions (E8). The same procedure was applied 
for pleural fluid specimens. The BinaxNOW® test for Legionella pneumophila urinary 
antigen was performed on urine specimens that had been stored at -80°C following 
collection. 
Respiratory pathogen multiplex PCR
The nasopharyngeal aspirate (NPA) specimens were refrigerated immediately following 
collection and then divided into aliquots before being stored at -80°C in Universal 
Transport Medium (Copan, Brescia, Italy) for later batch-testing. Total nucleic acids were 
extracted from 300μl aliquots of each specimen with the Qiagen BioRobotÒ Universal 
System using the QIAamp One-For-All nucleic acid kit (Qiagen, Manchester, UK). Influenza 
A and B viruses were detected by real-time reverse transcription polymerase chain 
reaction (qRT-PCR) using the CDC Human Influenza RT-PCR diagnostic panel (CDC 
Influenza Division) (E9). Adenovirus, bocavirus, Chlamydia pneumoniae, coronaviruses 
229E, HKU1, OC43 and NL63, enterovirus, human metapneumovirus (hMPV), 
Mycoplasma pneumoniae, parainfluenza virus types 1, 2, 3 and 4, parechovirus, 
respiratory syncytial viruses (RSV) and rhinovirus were detected using the FTD Respiratory 
Pathogens 33 kit (Fast-track Diagnostics, Luxembourg) (E10). The results for the other 
organisms detected by the FTD 33 kit were disregarded. 5 or 10 μL of nucleic acid extract 
was used in each qRT-PCR reaction in combination with the AgPath one-step RT-PCR 
reagents (Applied Biosystems, Foster City, California, USA). For both kits, PCR conditions 
were according to the manufacturer’s instructions. For the CDC Human Influenza RT-PCR 
diagnostic panel, samples with cycle threshold (Ct)-value <40 were recorded as positive; 
for the FTD 33 kit a cycle threshold (Ct)-value <33 was regarded as positive. Appropriate 
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negative and positive control specimens were run alongside each reaction. 
Mycobacterial diagnostic tests
Sputum and pleural fluid microscopy were performed according to standard procedures. 
Briefly, the most viscous part of the sputum specimen was aspirated and expelled onto a 
dry glass slide, spread to make a thin smear and stained using the Auramine O method. 
Pleural fluid specimens were concentrated by centrifugation prior to smear preparation. 
Smear specimens were each examined twice by two independent readers using LED 
fluorescence microscopy and reported according to standard criteria; discordant results 
prompted review by a third reader. All sample smears graded as scanty, 1+, 2+, and 3+ 
were defined as acid-fast bacilli (AFB) smear-positive.
Mycobacterial culture was performed according to standard procedures using the 
BACTEC MGIT 960 Mycobacterial Detection System (Becton Dickinson Diagnostic Systems, 
Sparks, Maryland, USA) as previously described (E11, E12). Briefly, following 
decontamination in sodium hydroxide and concentration by centrifugation, sputum and 
pleural fluid specimens were inoculated into mycobacterial growth indicator tubes (MGIT) 
tubes and incubated at 37°C in the BACTEC MGIT automated liquid culture system for up 
to 44 days. Cultured isolates identified as AFB on ZN microscopy were positively 
confirmed as Mycobacterium tuberculosis complex by microscopic cording and MPT-64 
lateral flow assay (Capilia; TAUNS Laboratories, Numazu, Japan). AFB isolates that were 
negative on either confirmatory test were inoculated onto plain Löwenstein-Jensen (LJ) 
media and incubated at 25°C, 37°C and 45°C and onto paranitrobenzoic acid (PNB) and 
incubated at 37°C. Isolates that grew on LJ media at 37°C only were classified as M. 
tuberculosis. Those that grew at 25°C or 45°C or on PNB were classified as 
nontuberculous mycobacteria and not speciated further. Positive cultures that did not 
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reveal AFB on microscopy were re-cultured using a stored aliquot of the primary 
specimen; if the same result was obtained, they were classified as contaminants or false 
positives. 
The Cepheid Xpert MTB/RIF assay (Cepheid, Sunnyvale, California, USA) is a self-
contained, fully integrated, automated rapid diagnostic system that uses nested real-time 
PCR to detect M. tuberculosis genomic DNA in sputum and other clinical specimens (E13). 
The assay was performed in accordance with the manufacturer’s instructions (E14).
Assignment of aetiology
A bacterial pathogen was determined to be present if: i) detected on blood or pleural 
fluid culture; ii) S. pneumoniae antigen was detected in urine or pleural fluid; iii) L. 
pneumophila antigen was detected in urine; or iv) C. pneumoniae or M. pneumoniae was 
detected by PCR in NPA. Certain bacterial blood culture isolates were considered to be 
contaminants. Mycobacterial infection was determined to be present if detected in 
sputum or pleural fluid by mycobacterial culture; or if Mycobacterium tuberculosis was 
detected by Xpert MTB/RIF assay. Positive AFB smear microscopy of sputum or pleural 
fluid in the absence of positive culture or Xpert MTB/RIF assay was assumed to be M. 
tuberculosis infection. Respiratory viral diagnosis was based on detection by PCR in NPA.
Data management
The clinical data were collected in paper-based CRFs and subsequently converted to 
electronic form using Intelligent Character Recognition scanning software (TeleForm; 
Cardiff Software Developers, Cardiff, UK). Prior to scanning the CRFs were checked by the 
clinical team and subsequently by study investigators (SA, AH, HJ and JH) and any 
discrepancies were queried. Automated validation checks were built in to the character 
recognition scanning process to identify outliers and erroneous values. Once all data were 
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entered into the study database, further systemic data checks were performed to detect 
potential errors, which were checked and corrected to create a final dataset.
Statistical methods
Statistical analyses were performed with Stata version 12.1 (StataCorp; Texas, US). The 
statistical methods for comparing microbial aetiology by radiographic and HIV status and 
for identifying independent risk factors for 30-day mortality are detailed in the main 
manuscript. The association of microbial aetiology with 30-day mortality for the most 
commonly identified pathogens (i.e. S. pneumoniae, M. tuberculosis and influenza) was 
estimated by multivariable logistic regression analysis with age, sex and HIV status 
included as covariates. 
The inter-observer variability of chest radiograph interpretation between the three 
readers was assessed by calculating average percentage agreement and kappa coefficient 
with estimated 95% confidence intervals (E15, E16). The kappa coefficient was 
interpreted as follow: <0, poor agreement; 0-0.2, slight agreement; 0.21-0.4, fair 
agreement; 0.41-0.6, moderate agreement; 0.61-0.8, substantial agreement; 0.81-1.0, 
almost perfect agreement.
CAP severity assessment tools
The following CAP severity-assessment tools were calculated as published and their 
prognostic performance to predict 30-day mortality was assessed. 
 CURB65: One point awarded for each of the following components present: 
confusion; urea >7 mmol/L; respiratory rate 30/min; systolic blood pressure <90 
mmHg or diastolic blood pressure 60 mmHg; age 65 years (E17).
 CRB65: Derived as per CURB65 with the exclusion of urea >7 mmmol/L (E17).
 SMRT-CO: Summation of points for each of the following components present: 
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systolic blood pressure <90 mmHg (2 points); multilobar involvment (1 point); 
respiratory rate 25/min if 50 years or 30/min if >50 years (1 point); heart rate 
125/min (1 point); confusion (1 point); oxygen saturations 93% if 50 years or 
90% if >50 years (2 points; E18).
 Modified IDSA/ATS minor criteria: One point awarded for each of the following 
components present: respiratory rate 30/min; oxygen saturations 90% (used as 
a surrogate for arterial oxygen pressure/fraction of inspired oxygen (PaO2/FiO2) 
ratio 250 criterion included in the published tool); multilobar infiltrates; 
confusion/disorientation; urea 7.1 mmol/L; white blood cell count <4 x109 
cells/L; platelets <100 x109 cells/L; temperature <36C; systolic blood pressure < 
90 mmHg (used as a surrogate for hypotension requiring aggressive fluid 
resuscitation; E19).
 SWAT-Bp: One point awarded for each of the following components present: male 
sex; wasting; non-ambulatory status; temperature <35C or >38C; systolic blood 
pressure <100 mmHg or diastolic blood pressure <60 mmHg (E20).
To calculate the prognostic performance characteristics of severity assessment tool, 
the recommended cutoffs used to define “severe pneumonia” were used: CURB65 3; 
CRB65 2; SMRT-CO 2; modified IDSA/ATS minor criteria 3; and SWAT-Bp 3. For 
each severity score, sensitivity, specificity, positive and negative predictive values, 
positive and negative likelihood ratios and area under the receiver-operating 
characteristic curve with 95% confidence intervals were calculated using standard 
methods. Patients with incomplete data were excluded from the analysis.
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SUPPLEMENTAL RESULTS
Supplemental Table E1. Demographic, clinical and radiographic characteristics of 459 
Malawian adults hospitalised with community-acquired pneumonia.
Characteristic No. (%) of episodes
Demographics
Male sex 285/459 (62.1)
Age (yrs)*
18-24
25-34
35-44
45-54
56-64
≥65
34.7
53/459
185/459
136/459
43/459
24/459
18/459
(29.4-41.9)
(11.6)
40.3)
(29.6)
(9.4)
(5.2)
(3.9)
Socioeconomic factors
Employment status
Paid employment
Self-employed
Unemployed
Other
157/455
152/455
120/455
26/455
(34.5)
(33.4)
(26.4)
(5.7)
Highest educational level attended
None
Primary
Secondary
Higher
45/451
242/451
152/451
12/451
(10.0)
(53.7)
(33.7)
(2.7)
Main household water source
River
Borehole/well
Public tap/standpipe
Piped to dwelling
3/458
128/458
247/458
80/458
(0.7)
(28.0)
(53.9)
(17.5)
Difficulty obtaining food
Often
Sometimes
Never
35/458
202/458
221/458
(7.6)
(44.1)
(48.3)
Main cooking fuel
Firewood
Charcoal
Paraffin
Electricity
117/458
298/458
6/458
37/458
(25.6)
(65.0)
(1.3)
(8.1)
HIV status
HIV positive†
Newly diagnosed
355/453
124/355
(78.4)
(34.9)
CD4 cell count (cells/mm3)†
All HIV-positive*
<50
50-199
≥200
Newly diagnosed HIV-positive*
99
88/315
158/315
69/315
93
(44-193)
(27.9)
(50.2)
(21.9)
(43-179)
ART use in known HIV-positive† 189/227 (83.3)
ART duration†
<3 months
3-12 months
>12 months
34/157
35/157
89/157
(21.7)
(22.3)
(56.1)
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Characteristic No. (%) of episodes
CPT use on admission†
All HIV-positive
Known HIV-positive
151/355
151/188
(42.5)
(80.3)
Medical history
Any other comorbid condition 31/451 (6.9)
Chronic lung disease‡ 15/452 (3.3)
Chronic heart disease§ 3/452 (0.7)
Hypertension 8/452 (1.8)
Cancer 5/452 (1.1)
Chronic kidney disease 1/452 (0.2)
Liver disease 1/452 (0.2)
Stroke 5/452 (1.1)
Epilepsy 1/452 (0.2)
Dementia 2/452 (0.4)
Previous tuberculosis ll 84/458 (18.3)
Previous pneumonia in last 5 years** 108/457 (23.6)
Pregnancy 2/174 (1.2)
Current smoker 50/457 (10.9)
Regular alcohol intake 122/456 (26.8)
Pre-hospital attendance & treatment
Pre-admission symptom duration*
1-3 days
4-7 days
8-10 days
11-14 days
7
63/457
214/457
50/457
130/457
(5-12)
(13.8)
(46.8)
(10.9)
(28.5)
Travel time to hospital
<1 hour
1-2 hours
>2 hours
114/455
245/455
96/455
(25.0)
(53.9)
(21.1)
Attended another health facility†† 283/458 (61.8)
Prior review
Primary health centre
Private clinic
Other hospital
Pharmacy
Traditional healer
283/458
230/283
49/283
7/283
1/283
2/283
(61.8)
(81.2)
(17.3)
(2.5)
(0.4)
(0.7)
Antibiotics within 2 weeks‡‡ 280/455 (61.5)
Antimalarials within 2 weeks 79/457 (17.3)
Traditional remedies within 2 weeks 40/456 (8.8)
Clinical features
Symptoms
Cough
Sputum production
Dyspnoea
Fever
Weight loss
Night sweats
451/458
357/458
440/458
457/458
277/458
299/457
(98.5)
(78.0)
(96.1)
(99.8)
(60.5)
(65.4)
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Characteristic No. (%) of episodes
Examination features
Crepitations
Bronchial breathing
Pleural effusion
Confusion/disorientation
Inability to stand
Oral thrush
Kaposi’s sarcoma
387/457
167/458
79/457
5/458
87/459
28/458
14/458
(84.7)
(36.4)
(17.3)
(1.1)
(19.0)
(6.1)
 (3.1)
Baseline laboratory results
Haemoglobin (g/dL)*
<8
11
74/449
(9.0-12.8)
(16.5)
White blood cells (x 109 cells/L)*
<4
≥15
7.7
67/448
x63/448
(5.0-11.4)
(15.0)
(14.1)
Urea (mmol/L)*
>7
4.8
137/450
(3.3-8.0)
(30.4)
Creatinine (μmol/L)*
>120
76
76/448
(59-100)
(17.0)
Radiological features§§
Radiographic pneumonia 317/417 (76.0)
Consolidation 251/313 (80.2)
Multilobar involvement 73/247 (29.6)
Cavitation 20/317 (6.3)
Pleural effusion 118/315 (37.5)
Outcomellll
Inpatient mortality 51/457 (11.2)
Day 30 mortality 64/439 (14.6)
Day 90 mortality 87/418 (20.8)
Definition of abbreviations: ART = antiretroviral therapy; BP = blood pressure; CPT = 
co-trimoxazole preventative therapy; IQR = interquartile range.
Data are n/N (%) unless indicated by * where median and interquartile range are 
shown.  Variation in denominator reflects missing data unless further specified.
†HIV status missing in 6 patients; CD4 count missing in 40 of all with HIV; CPT and 
ART usage missing in 4 and 43, respectively, with known HIV; ART duration missing 
in 32 reporting ART use.
‡Chronic lung disease includes asthma, COPD and bronchiectasis. 
§Chronic heart disease includes congestive cardiac failure, cor pulmonale and 
dilated cardiomyopathy. 
llAny previous episode of treated tuberculosis regardless of site and confirmation. 
**Any prior episode within the last 5 years of a syndrome compatible with lower 
respiratory tract infection reviewed in a healthcare facility and treated with 
antibiotics. 
††Included attendance to other hospital, health centre, private clinic, traditional 
healer or pharmacy. 
‡‡Excluded co-trimoxazole prophylaxis in HIV-infected individuals.
§§Chest radiographs available in 421 patients; reports based on consensus grading 
of assessors and denominator may vary when consensus not obtained.  
llllStatus at hospital discharge, day 30 and day 90 missing in 2, 20 and 41, 
respectively.
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Supplemental Table E2. Radiological features with inter-report agreement in Malawian adults hospitalised with community-acquired 
pneumonia. 
Individual scorer’s assessment All scorer’s agreement
Radiologist 1 
(n=419)*
Radiologist 2 
(n=407)*
Clinician
(n=417)*
Consensus 
interpretation† Avg. agree (%)‡ Kappa (95% CI) ‡
Radiographic pneumonia 323 (77.1) 297 (73.0) 314 (75.3) 317/417 (76.0) 90.6 0.75 (0.69-0.81)
Any parenchymal abnormality 300 (71.6) 266 (65.3) 268 (64.3) 282/414 (68.1) 86.0 0.68 (0.61-0.74)
Consolidation 245 (58.5) 251 (61.7) 260 (62.4) 251/413 (60.8) 83.3 0.65 (0.59-0.70)
Quality
Confluent
Patchy
159/244
85/244
(65.2)
(34.9)
135/251
116/251
(53.8)
(46.2)
161/260
99/260
(61.9)
(38.1)
145/233
88/233
(62.2)
(37.8)
74.5 0.46 (0.37-0.55)
Extent
Segmental
Lobar
Multifocal
77/245
73/245
95/245
(31.4)
(29.8)
(38.8)
78/250
73/250
99/250
(31.2)
(29.2)
(39.6)
83/260
89/260
88/260
(31.9)
(34.2)
(33.9)
62/225 
73/225 
90/225 
(27.6)
(32.4)
(40.0)
65.9 0.48 (0.42-0.56)
Multilobar 85/255 (34.7) 65/251 (25.9) 76/260 (29.2) 73/247 (29.6) 83.3 0.55 (0.46-0.63)
Cavitation 27/417 (6.5) 26/406 (6.4) 15/416 (3.6) 20/418 (4.8) 94.9 0.51 (0.35-0.65)
Reticulonodular change 140 (33.4) 35 (8.6) 24 (5.8) 35/418 (8.4) 76.9 0.15 (0.07-0.24)
Miliary appearance 2/414 (0.5) 2/405 (0.5) 8/416 (1.9) 2/417 (0.5) 98.4 0.17 (-0.01-0.34)
Pleural effusion 111 (26.5) 106 (26.0) 155 (37.2) 118/416 (28.4) 83.7 0.61 (0.55-0.67)
Pneumothorax 2/410 (0.5) 1/406 (0.3) 3/405 (0.7) 2/416 (0.5) 99.3 0.32 (-0.02-0.49)
Mediastinal lymphadenopathy 40 (9.6) 34 (8.4) 50 (12.0) 28/417 (6.7) 87.4 0.30 (0.19-0.42)
Volume loss 76 (18.1) 35 (8.6) 44 (10.6) 30/421 (7.1) 84.1 0.28 (0.17-0.38)
Bronchiectasis 31 (7.4) 8 (2.0) 3 (0.7) 3/421 (0.7) 93.7 0.03 (-0.04-0.11)
Definition of abbreviations: CI = confidence interval. 
Data are n/N (%) unless otherwise specified. Chest radiographs were available in 421 of 459 patients; chest radiographs unavailable because of death prior to 
radiograph (n=14), hospital discharge without radiograph or prior to digital capture (n=18) and unclear reason (n=6). 
*Radiologist 1, radiologist 2 and clinician considered 2, 14 and 4 radiographs, respectively, as uninterpretable. 
†Consensus values calculated by majority rating of all assessors; denominator may vary when consensus not obtained, most notably for specific features of 
consolidation which were reported only when assessor regarded consolidation as present. 
‡Average agreement and three-way kappa (estimated 95% confidence intervals) calculated for all three assessors.  
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Supplemental Table E3. Clinical features and outcome by chest radiograph availability and 
radiographic status in Malawian adults hospitalised with community-acquired 
pneumonia. 
Chest radiograph available (n=417)
Characteristic Radiographic 
pneumonia 
(n=317)
No radiographic 
pneumonia 
(n=100)
P†
Chest radiograph 
unavailable
(n=38)
P‡
Male sex 210/317 (66.3) 59/100 (49.0) 0.002 23/38 (60.5) 0.85
Age* 35 (30-42) 33 (27-38) 0.01§ 37 (30-44) 0.22§
HIV positivell 247/313 (78.9) 73/98 (74.5)) 0.36 31/38 (81.6) 0.60
Pre-presentation symptoms 
>7 days
122/316 (38.6) 42/103 (42.0) 0.55 15/37 (40.5) 0.90
Temperature <35 or ≥40 °C 10/317 (3.2) 3/100 (3.0) 1.00** 1/38 (2.6) 1.00**
Systolic BP <90 mmHg 61/314 (19.4) 13/99 (13.1) 0.15 11/37 (29.7) 0.08
Diastolic BP ≤60 mmHg 98/314 (31.2) 26/99 (26.3) 0.35 16/37 (43.2) 0.10
Heart rate ≥125 /min 127/316 (40.2) 35/100 (54.0) 0.35 14/38 (36.8) 0.80
Respiratory rate ≥30 /min 155/307 (50.5) 36/98 (36.7) 0.02 18/37 (48.7) 0.86
Oxygen saturations <90 % 52/308 (16.9) 7/100 (7.0) 0.02 13/38 (34.2) 0.002
BMI <18.5 kg/m2 94/306 (30.7) 28/98 (28.6) 0.69 10/37 (27.0) 0.69
Inability to stand 51/317 (16.1) 18/100 (18.0) 0.65 16/38 (42.1) <0.001
Haemoglobin <8 g/dL 45/313 (14.4) 22/96 (22.9) 0.048 6/37 (16.2) 0.98
White blood cells <4 x109 /L 41/312 (13.1) 19/96 (19.8) 0.11 7/37 (18.9) 0.49
Urea >7 mmol/L 98/313 (31.3) 27/98 (27.6) 0.48 12/37 (32.4) 0.80
Creatinine >120 μmol/L 46/313 (14.7) 22/96 (22.9) 0.06 7/37 (18.9) 0.72
Day 30 mortality 31/304 (10.2) 16/98 (16.3) 0.10 17/36 (47.2) <0.001
Definition of abbreviations: BMI = body mass index; BP = blood pressure
Data are n/N (%) unless indicated by * where median and interquartile range are shown. Variation in denominator 
compared to column header reflecting missing data.
†Comparison between patients with and without radiographic pneumonia by χ2 test unless otherwise stated. 
‡Comparison between all patients with and all without available interpretable chest radiograph by χ2 test unless otherwise 
stated; 4 patients who had chest radiograph but without consensus interpretation excluded from analysis. 
§Wilcoxon rank-sum test
llHIV status missing in 6 patients
**Fisher’s exact test
††Status at day 30 missing in 19 patients.
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Supplemental Table E4. Intravenous antibiotic treatment duration, length of stay and 30-
day mortality by antibiotic treatment group in Malawian adults hospitalised with 
community-acquired pneumonia. 
Antibiotic treatment group n Intravenous antibiotic 
duration, days
Median (IQR)
Length of stay, days
Median (IQR)
30-day mortality
n/N (%)
Ceftriaxone monotherapy 251/450 (55.8) 5 (3-7) 7 (4-9) 38/242 (15.7)
Ceftriaxone-based 
combination 
114/450 (25.3) 5 (3-7) 8 (5-11) 15/108 (13.9)
Penicillin & Chloramphenicol 65/450 (14.4) 4 (3-6) 6 (4-8) 8/61 (13.1)
Penicillin & Chloramphenicol-
based combination
15/450 (3.3) 3 (2-7) 12 (4-18) 0/14 (0)
Amoxicillin (oral) 5/450 (1.1) - - 9 (5-11) 1/5 (20)
Definition of abbreviations: IQR = interquartile range.
Patients assigned to treatment group on the basis of all antibiotics prescribed during admission, excluding anti-tuberculous 
treatment. Patients in ‘combination’ groups received additional intravenous and/or oral agents. Data missing in 8 patients. 
Supplemental Table E5. Organism identification by specimen type and diagnostic test 
stratified by HIV status. 
Organism
All*
(n=459)
HIV-positive
(n=355)
HIV-negative
(n=98)
Blood cultures†
Streptococcus pneumoniae 5/450 (1.1) 4/350 (1.1) 1/94 (1.1)
Salmonella Typhi 9/450 (2.0) 3/350 (0.9) 5/94 (5.3)
Salmonella Typhimurium 6/450 (1.3) 6/350 (1.7) 0/94 (0)
Salmonella Enteritidis 1/450 (0.2) 1/350 (0.3) 0/94 (0)
Staphylococcus aureus 2/450 (0.4) 1/350 (0.3) 1/94 (1.1)
Escherichia coli 2/450 (0.4) 2/350 (0.6) 0/94 (0)
Enterobacter cloacae 1/450 (0.2) 1/350 (0.3) 0/94 (0)
Pleural fluid culture
Salmonella Typhi 1/31 (3.2) 1/19 (5.3) 0/11 (0)
Mycobacterium tuberculosis 7/35 (20.0) 4/22 (18.2) 2/12 (16.7)
Streptococcus pneumoniae antigen test
Urine 95/433 (21.9) 67/333 (20.1) 28/94 (29.8)
Pleural fluid 3/31 (9.7) 1/20 (5) 2/10 (20)
Legionella pneumophila antigen test
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Urine 0/193 (0) 0/154 (0) 0/38 (0)
Sputum mycobacterial diagnostic tests
AFB smear microscopy 36/305 (11.8) 30/241 (12.4) 6/60 (10.0)
Sputum culture
Mycobacterium tuberculosis 60/273 (22.0) 54/217 (24.9) 6/52 (11.5)
NTM 8/273 (2.9) 5/217 (2.3) 3/52 (5.8)
Xpert MTB/RIF 56/308 (18.2) 46/244 (18.9) 10/60 (16.7)
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Organism
All
(n=459)
HIV-positive
(n=355)
HIV-negative
(n=98)
Multiplex PCR on nasopharyngeal aspirate
Adenovirus 35/455 (7.7) 30/355 (8.5) 5/98 (5.1)
Bocavirus 13/455 (2.9) 13/355 (3.6) 0/98 (0)
Chlamydia pneumoniae 2/455 (0.4) 0/355 (0) 2/98 (2)
Coronavirus HKU1 3/455 (0.7) 3/355 (0.9) 0/98 (0)
Coronavirus 229E 19/455 (4.2) 16/355 (4.5) 3/98 (3.1)
Coronavirus OC43 6/455 (1.3) 6/355 (1.7) 0/98 (0)
Coronavirus NL63 5/455 (1.4) 5/355 (1.4) 0/98 (0)
Enterovirus 5/455 (1.1) 5/355 (1.4) 0/98 (0)
Influenza A 19/454 (4.2) 13/354 (3.7) 5/98 (5.1)
Influenza B 21/454 (4.6) 17/354 (4.8) 4/98 (4.1)
Metapneumovirus 9/455 (2) 8/355 (2.3) 1/98 (1.0)
Mycoplasma pneumoniae 6/455 (1.3) 6/355 (1.7) 0/98 (0)
Parainfluenza 1 2/455 (0.4) 1/355 (0.3) 1/98 (1.0)
Parainfluenza 2 6/455 (1.3) 6/355 (1.7) 0/98 (0)
Parainfluenza 3 7/455 (1.5) 7/355 (2) 0/98 (0)
Parainfluenza 4 3/455 (0.7) 2/355 (0.6) 0/98 (0)
Parechovirus 5/455 (1.1) 5/355 (1.4) 0/98 (0)
Rhinovirus 17/455 (3.7) 15/355 (4.2) 2/98 (2)
RSV 8/455 (1.8) 4/355 (1.1) 3/98 (3.1)
Definition of abbreviations: NTM = nontuberculous mycobacteria; RSV = respiratory syncytial virus. 
Data are n/N (%) specimens positive for specific organism; variation in denominator reflects the 
availability of the relevant clinical specimen.
*In the 6 patients with unknown HIV status the following positive results were obtained: blood culture - S. 
Typhi, 1; pleural fluid culture – M. tuberculosis, 1; nasopharyngeal aspirate PCR – 1 each of influenza A, 
parainfluenza and RSV.
†A further 12 blood cultures (3%) yielded organisms regarded as contaminants: coagulase-negative 
Staphylococci, 8; Micrococcus spp., 2; Bacillus spp., 2.
Page 57 of 68  AJRCCM Articles in Press. Published on 09-January-2019 as 10.1164/rccm.201807-1333OC 
 Copyright © 2019 by the American Thoracic Society 
CAP in Malawian adults – Online Data Supplement
18
Supplemental Table E6. Aetiology of community-acquired pneumonia in Malawian adults stratified by radiological appearance and HIV status. 
Radiographic pneumonia (n=317)* No radiographic pneumonia (n=100)*
Organism All HIV-pos. HIV-neg. All HIV-pos. HIV-neg. P for difference†
Streptococcus pneumoniae 83/316 (26.3) 56/247 (22.7) 27/65 (41.5) 8/100 (8.0) 5/73 (6.9) 3/25 (12) <0.001
Salmonella Typhi 2/309 (0.7) 2/243 (0.8) 0/62 (0) 8/99 (8.1) 2/72 (2.8) 5/25 (20) <0.001
Nontyphoidal Salmonella‡ 1/309 (0.3) 1/243 (0.4) 0/62 (0) 5/99 (5.1) 5/72 (6.9) 0/25 (0) <0.001
Other GNEB§ 2/309 (0.7) 2/243 (0.8) 0/62 (0) 1/99 (1) 1/72 (1.4) 0/25 (0) 0.66
S. aureus 1/309 (0.3) 0/243 (0) 1/62 (1.6) 0/99 (0) 0/72 (0) 0/25 (0) 0.53
Atypical bacteriall 5/314 (1.6) 4/247 (1.6) 1/66 (1.5) 1/99 (1) 0/73 (0) 1/25 (4) 0.66
Mycobacterium tuberculosis 58/232 (25) 47/186 (25.3) 10/42 (23.8) 13/68 (19.1) 13/50 (26) 0/17 (0) 0.39
NTM 3/194 (1.6) 2/158 (1.3) 1/33 (3) 4/57 (7.0) 2/41 (4.9) 2/15 (13.3) 0.046
Influenza 25/313 (8) 20/246 (8.1) 4/66 (6.1) 11/99 (11.1) 9/73 (12.3) 2/25 (8) 0.26
Adenovirus 22/314 (7) 19/247 (7.7) 3/66 (4.5) 7/99 (7.1) 5/73 (6.9) 2/25 (8) 0.95
Coronavirus 22/314 (7) 19/247 (7.7) 3/66 (4.6) 9/99 (9.1) 9/73 (12.3) 0/25 (0) 0.43
Parainfluenza 10/314 (3.2) 9/247 (3.6) 1/66 (1.5) 6/99 (6.1) 5/73 (6.9) 0/25 (0) 0.34
Rhinovirus 11/314 (3.5) 9/247 (3.6) 2/66 (3) 4/99 (4) 4/73 (5.5) 0/25 (0) 0.76
Bocavirus 9/314 (2.9) 9/247 (3.6) 0/66 (0) 3/99 (3) 3/73 (4.1) 0/25 (0) 0.85
Metapneumovirus 9/314 (2.9) 8/247 (3.2) 1/66 (1.5) 0/99 (0) 0/73 (0) 0/25 (0) 0.09
RSV 4/314 (1.3) 1/247 (0.4) 2/66 (3) 3/99 (3) 2/73 (2.7) 1/25 (4) 0.16
Enterovirus 2/314 (0.6) 2/247 (0.8) 0/66 (0) 1/99 (1) 1/73 (1.4) 0/25 (0) 0.66
Parechovirus 2/314 (0.6) 2/247 (0.8) 0/66 (0) 1/99 (1) 1/73 (1.4) 0/25 (0) 0.66
No pathogen detected 123/317 (38.8) 95/247 (38.5) 26/66 (39.4) 37/100 (37) 25/73 (34.3) 11/25 (48) 0.85
Definition of abbreviations: GNEB = Gram-negative enteric bacilli; NTM = nontuberculous mycobacteria; RSV = respiratory syncytial virus. 
Data are n/N (%). Denominators indicate number of patients with at least one relevant test available. S. pneumoniae diagnosis based on combination of blood and pleural fluid 
culture and antigen assay of urine and pleural fluid. M. tuberculosis based on combination of sputum microscopy, culture and Xpert MTB/RIF and pleural fluid culture. Other 
organisms based on single test. *In the 42 patients without available chest radiograph or consensus report for radiographic pneumonia, the following organisms were detected: S. 
pneumoniae, 7; nontyphoidal Salmonella, 1; S. aureus, 1; atypical bacteria, 2; M. tuberculosis, 4; NTM, 1; influenza, 4; adenovirus, 6; parainfluenza, 1; rhinovirus, 2; bocavirus, 1; 
RSV, 1; enterovirus, 2; parechovirus, 2; no pathogen detected, 21. †Association of organism with radiological appearance controlling for effect of HIV by Mantel-Haenszel χ2 test. 
‡S. Enteritidis and S. Typhimurium combined. §Escherichia coli and Enterobacter cloacae combined.  ll Chlamydia pneumoniae and Mycoplasma pneumoniae combined. 
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Supplemental Table E7. Radiological features of community-acquired pneumonia in 
Malawian adults stratified by microbial aetiology. 
Organism
Radiographic feature* Streptococcus 
pneumoniae† 
(n=69)
Mycobacterium 
tuberculosis‡
(n=51)
Influenza
(n=16)§
Any parenchymal abnormality 65/68 (95.6) 43/51 (84.3) 16/16 (100)
Consolidation 61/68 (89.7) 40/51 (78.4) 11/16 (68.8)
Quality§
Confluent
Patchy
46/60
14/60
(76.7)
(23.3)
17/37
20/37
(46.0)
(54.1)
4/9
5/9
(44.4)
(55.6)
Extent§
Segmental
Lobar
Multifocal
11/57
23/57
23/57
(19.3)
(40.4)
(40.4)
5/37
8/37
24/37
(13.5)
(21.6)
(64.9)
1/8
3/8
4/8
(12.5)
(37.5)
(50.0)
Multilobar 20/61 (32.8) 20/51 (39.2) 3/14 (21.4)
Cavitation 2/69 (2.9) 6/51 (11.8) 0/16 (0)
Reticulonodular change 4/69 (5.8) 14/51 (27.5) 3/16 (18.8)
Miliary appearance 0/69 (0) 0/50 (0) 0/16 (0)
Pleural effusion 22/69 (31.9) 23/50 (46.0) 3/16 (18.8)
Mediastinal lymphadenopathy 2/69 (2.9) 8/51 (15.7) 1/16 (6.3)
Data area n/N (%). Analysis restricted to patients with radiographic pneumonia who did not have co-infection 
involving more than one of S. pneumoniae, M. tuberculosis and influenza to achieve three mutually exclusive 
groups. 
*Based on consensus values of all assessors; denominator may vary when consensus not obtained. 
†Additional 6 patients with M. tuberculosis and 7 with influenza co-infection excluded. Other co-infections 
detected in 24: bacterial, 5; viral, 18; mixed viral-non-tuberculous mycobacterial, 1. 
‡Additional 6 patients with S. pneumoniae and 1 with influenza co-infection excluded. Other co-infections 
detected in 15: bacterial, 2; viral, 11; mixed viral-bacterial, 2.
§Additional 8 patients with S. pneumoniae and 1 with M. tuberculosis co-infection excluded. Other co-
infections detected in 4: bacterial, 1; viral, 3.
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Supplemental Table E8. Matrix showing co-infection combinations in Malawian adults 
hospitalised with community-acquired pneumonia. 
S.
 p
ne
um
on
ia
e
S.
 ty
ph
i
N
TS
O
th
er
 G
N
EB
S.
 a
ur
eu
s
At
yp
ic
al
 b
ac
te
ria
M
. t
ub
er
cu
lo
sis
N
TM
In
flu
en
za
Ad
en
ov
iru
s
Co
ro
na
vi
ru
se
s
Pa
ra
in
flu
en
za
Rh
in
ov
iru
s
Bo
ca
vi
ru
s
M
et
ap
ne
um
ov
iru
s
RS
V
En
te
ro
vi
ru
s
Pa
re
ch
ov
iru
s
TO
TA
L
S. pneumoniae 40 0 0 0 0 0 7 2 6 7 5 4 6 1 3 2 0 0 73
S. typhi 2 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 4
NTS 2 0 0 0 0 2 0 1 1 1 0 0 0 0 0 0 5
Other GNEB 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1
S. aureus 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1
Atypical bacteria 1 1 0 0 0 0 1 0 0 0 0 0 0 3
M. tuberculosis 42 0 2 8 3 4 3 1 2 1 0 0 68
NTM 2 0 2 2 1 1 0 0 0 0 0 8
Influenza 19 1 3 1 1 1 0 1 0 0 31
Adenovirus 8 1 1 0 0 1 0 0 0 23
Coronaviruses 10 0 2 3 0 0 0 0 25
Parainfluenza 4 2 0 1 0 0 0 14
Rhinovirus 3 0 0 0 1 1 13
Bocavirus 3 0 2 0 0 8
Metapneumovirus 1 0 0 0 6
RSV 2 0 0 7
Enterovirus 0 1 1
Parechovirus 0 1
Definition of abbreviations: GNEB = Gram-negative enteric bacilli; NTM = nontuberculous mycobacteria; NTS 
= nontyphoidal Salmonella; RSV = respiratory syncytial virus.
Analysis performed in 307 patients with complete results available for blood culture, pneumococcal urine 
antigen testing, sputum mycobacterial culture and/or Xpert MTB/RIF, nasopharyngeal aspirate multiplex 
PCR; 152 excluded for lacking results for one or more of these investigations. Darkly shaded squares indicate 
mono-infection.
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Supplemental Table E9. Association of aetiology with 30-day mortality for three 
commonest pathogens in Malawian adults with community-acquired pneumonia. 
30-day mortality
Organism
No. (%) aOR (95% CI)* P
Streptococcus pneumoniae
Yes
No
7/94 
57/344 
 
(7.5)
(16.6) 0.40 (0.17-0.91)
0.03
Mycobacterium tuberculosis
Yes
No
17/74 
22/241 
 
(23.0)
(9.1) 2.44 (1.19-5.01)
0.02
Influenza
Yes
No
2/39 
61/396 
 
(5.1)
(15.4) 0.39 (0.09-1.67)
0.20
Definition of abbreviations: aOR = adjusted odds ratio; CI = confidence interval; 
IQR = interquartile range. 
Data are n/N (%). Status at day 30 determined in 439 of 459 patients overall; 
individual analyses for each pathogen restricted to those for whom relevant 
specimens available: S. pneumoniae (n=438); M. tuberculosis (n=315); 
influenza (n=435). 
*Odds ratios calculated by logistic regression and adjusted for age, sex and HIV 
status. 
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Supplemental Table E10. Association of candidate clinical and laboratory risk factors with 
30-day mortality in HIV-infected Malawian adults hospitalised with community-acquired 
pneumonia. 
Univariable analysis Multivariable analysis
Characteristic
Day 30 survivors
(n=288)
Day 30 mortality
(n=54) OR (95% CI) P aOR (95% CI) P
Male sex 170/288 (59.0) 45/54 (83.3) 3.47 (1.63-7.37) 0.001 1.94 (0.81-4.67) 0.14
Age (yrs) 34 (30-41) 36 (32-41) 1.01 (0.98-1.03) 0.72 1.00 (0.96-1.04) 0.98
Current smoker 23/286 (8.0) 3/54 (5.6) 0.67 (0.19-2.32) 0.53 - -
Pre-presentation 
symptoms >7 days
99/288 (34.4) 32/53 (60.4) 2.91 (1.59-5.31) 0.001 3.56 (1.60-7.93) 0.002
Temperature <35 or ≥40 
°C
10/288 (3.5) 1/54 (1.9) 0.52 (0.07-4.18) 0.54 -* -
Systolic BP <90 mmHg 58/284 (20.4) 15/54 (27.8) 1.50 (0.77-2.90) 0.23 - -
Heart rate ≥125 /min 117/287 (40.8) 33/54 (61.1) 2.28 (1.26-4.14) 0.007 3.06 (1.40-6.71) 0.005
Resp. rate ≥30 /min) 128/277 (46.2) 28/53 (52.8) 1.30 (0.72-2.35) 0.38 - -
Oxygen satn <90 % 33/282 (11.7) 23/54 (42.6) 5.60 (2.92-10.73) <0.0001 2.97 (1.28-6.88) 0.01
MUAC <230 mm 82/285 (28.8) 13/53 (24.5) 0.80 (0.41-1.58) 0.53 - -
Inability to stand 47/288 (16.3) 26/54 (48.2) 4.76 (2.57-8.84) <0.0001 4.25 (1.84-9.79) 0.001
Haemoglobin <8 g/dL 51/283 (18.0) 17/51 (33.3) 2.27 (1.18-4.38) 0.01 - -
White cell count 
<4 x 109/L
41/282 (14.5) 14/51 (27.5) 2.22 (1.11-4.47) 0.03 - -
Platelets <100 x 109/L 48/283 (17.0) 11/51 (21.6) 1.34 (0.64-2.81) 0.43 - -
Urea >7 mmol/L 90/285 (31.6) 22/50 (44.0) 1.70 (0.92-3.14) 0.09 - -
CD4 count <50 cells/mm3 65/257 (25.3) 23/47 (48.9) 2.83 (1.50-5.35) 0.001 2.30 (1.07-4.92) 0.03
Definition of abbreviations: BP = blood pressure; BMI = body mass index; CI = confidence interval; MUAC = mid-upper arm 
circumference; OR = odds ratio; Resp. = respiratory
For age (in italics) data shown as median and interquartile range. Otherwise data shown as n/N (%) with variation in 
denominator compared to column header reflecting missing data. Univariable and multivariable analyses by logistic 
regression. For age, odds ratio indicates change in risk of mortality with each year increase. 13 of 355 HIV-infected 
patients within study cohort excluded due to unknown 30-day outcome. Final multivariable analysis based on 287 
patients with complete results for all included parameters. 
*Excluded from multivariable analysis because of prevalence ≤5%. 
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Supplemental Table E11. Association of clinical and laboratory risk factors with 30-day 
mortality in hospitalised Malawian adults with radiographic community-acquired 
pneumonia. 
Univariable analysis Multivariable analysis
Characteristic
Day 30 survivors
(n=274)
Day 30 mortality
(n=31) OR (95% CI) P aOR (95% CI) P
Male sex 179/274 (65.3) 24/31 (77.4) 1.82 (0.76-4.38) 0.18 1.39 (0.53-3.61) 0.51
Age (yrs) 35 (30-42) 37 (32-44) 1.01 (0.98-1.03) 0.70 1.02 (0.98-1.05) 0.39
Current smoker 28/272 (10.3) 3/31 (9.7) 0.93 (0.27-3.27) 0.92 - -
Pre-presentation 
symptoms >7 days
99/273 (36.3) 19/31 (61.3) 2.78 (1.30-5.97) 0.009 3.30 (1.37-7.96) 0.008
HIV-positive 216/271 (79.7) 25/31 (80.7) 1.06 (0.41-2.71) 0.90 1.11 (0.36-3.42) 0.86
Temperature <35 or 
≥40 °C
10/274 (3.7) 0/31 (0) - - -* -
Systolic BP <90 mmHg 52/271 (19.2) 7/31 (22.6) 1.23 (0.50-3.00) 0.65 - -
Heart rate ≥125 /min 104/273 (38.1) 20/31 (64.5) 2.95 (1.36-6.41) 0.006 2.66 (1.08-6.57) 0.03
Resp. rate ≥30 /min) 134/265 (50.6) 16/30 (53.3) 1.12 (0.52-2.38) 0.77 - -
Oxygen satn <90 % 42/267 (15.7) 9/30 (30.0) 2.30 (0.98-5.36) 0.06 - -
MUAC <230 mm 79/270 (29.3) 5/30 (16.7) 0.48 (0.18-1.31) 0.15 - -
Inability to stand 41/274 (15.0) 10/31 (32.3) 2.71 (1.19-6.17) 0.02 2.63 (1.00-6.89) 0.05
Haemoglobin <8 g/dL 38/270 (14.1) 6/31 (19.4) 1.47 (0.56-3.81) 0.43 - -
White cell count 
<4 x 109/L
34/269 (12.7) 5/31 (16.1) 1.33 (0.48-3.70) 0.59 - -
Platelets <100 x 109/L 37/270 (13.7) 6/31 (19.4) 1.51 (0.58-3.93) 0.40 - -
Urea >7 mmol/L 83/270 (30.7) 13/31 (41.9) 1.63 (0.76-3.48) 0.21 - -
Multilobar 
consolidation
56/266 (21.1) 14/30 (46.7) 3.28 (1.51-7.13) 0.003 2.75 (1.17-6.47) 0.02
Cavitation 18/274 (6.6) 2/31 (6.5) 0.98 (0.22-4.44) 0.98 - -
Pleural effusion 98/272 (36.4) 16/31 (51.6) 1.86 (0.88-3.93) 0.10 - -
Definition of abbreviations: BP = blood pressure; BMI = body mass index; CI = confidence interval; MUAC = mid-upper arm 
circumference; OR = odds ratio; Resp. = respiratory
For age (in italics) data shown as median and interquartile range. Otherwise data shown as n/N (%) with variation in 
denominator compared to column header reflecting missing data. Univariable and multivariable analyses by logistic 
regression. For age, odds ratio indicates change in risk of mortality with each year increase. 
12 of 317 patients with radiographic pneumonia within study cohort excluded due to unknown 30-day outcome. Final 
multivariable analysis based on 278 patients with complete results for all included parameters. 
*Excluded from multivariable analysis because of prevalence ≤5%.
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Supplemental Table E12. Accuracy of pneumonia severity-assessment tools for predicting 30-day mortality in hospitalised Malawian adults 
with radiographic community-acquired pneumonia. 
Score group n*
Sensitivity % 
(95% CI)
Specificity %
(95% CI)
PPV %
(95% CI)
NPV %
(95% CI)
Positive LR
(95% CI)
Negative LR
(95% CI)
AUROC
(95% CI)
CURB65 ≥3 288 6.7 (0.8-22.1) 89.9 (85.6-93.3) 7.1 (0.9-23.5) 89.2 (84.8-92.7) 0.66 (0.17-2.65) 1.04 (0.94-1.15 0.53 (0.43-0.63)
CRB65 ≥2 292 20.0 (7.7-38.6) 79.8 (74.4-84.5) 10.2 (3.8-20.8) 89.7 (85.1-93.3) 0.99 (0.46-2.10) 1.00 (0.83-1.21) 0.50 (0.39-0.60)
SMRT-CO ≥2 280 89.7 (72.6-97.8) 36.7 (30.7-42.9) 14.1 (9.4-19.9) 96.8 (91.0-99.3) 1.42 (1.21-1.65) 0.28 (0.10-0.84) 0.66 (0.57-0.75)
Modified IDSA/ATS 
minor criteria ≥3
272 48.3 (29.4-67.5) 72.0 (65.9-77.6) 17.1 (9.7-27.0) 92.1 (87.3-95.5) 1.73 (1.13-2.64) 0.72 (0.50-1.03) 0.66 (0.56-0.75)
SWAT-Bp ≥3 297 40.0 (22.7-59.4) 65.9 (59.9-71.6) 11.7 (6.2-19.5) 90.7 (85.7-94.4) 1.17 (0.73-1.88) 0.91 (0.67-1.23) 0.54 (0.43-0.65)
Definition of abbreviations: AUROC = area under receiver-operating characteristic curve; CI = confidence interval; CURB65 = tool based on presence of confusion, urea >7mmol/L, respiratory rate 
≥30/min, systolic blood pressure <90mmHg and/or diastolic blood pressure ≤60mmHg, age ≥65 (29); CRB65 = as per CURB65 with exclusion of urea (29); IDSA/ATS = modified version of 
Infectious Disease Society of America/American Thoracic Society criteria based on presence of respiratory rate 30/min, oxygen saturations 90% (used as a surrogate for arterial oxygen 
pressure/fraction of inspired oxygen (PaO2/FiO2) ratio 250 criterion included in the published tool), multilobar infiltrates, confusion/disorientation, urea 7.1 mmol/L, white blood cell count <4 
x109 cells/L, platelets <100 x109 cells/L, temperature <36C, systolic blood pressure < 90 mmHg (used as a surrogate for hypotension requiring aggressive fluid resuscitation; 32); LR = likelihood 
ratio; NPV = negative predictive value; PPV = positive predictive value; SMRT-CO = tool based on presence of systolic blood pressure < 90 mmHg, multilobar consolidation, respiratory rate 
25/min if 50 years or 30/min if >50 years, heart rate 125/min, confusion and oxygen saturations 93% if 50 yrs or 90% if >50 yrs (31); SWAT-Bp = tool based on male sex, wasting, non-
ambulatory status, temperature <35C or >38C and systolic blood pressure <100 mmHg or diastolic blood pressure <60 mmHg (28). For each tool, the performance characteristics displayed are 
those using the scoring threshold for “severe CAP” as suggested by the authors. *Score calculated in varying number of patients depending on availability of results for component parameters.
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